PsyRx
Drug Development Using Biological Bioreactor Technology
Company Overview
Snapshot
Founded in October 2019 by Asher Holzer, Asher Holtzer, Itay Hecht, and Kobi Buxdorf, PsyRx operates with 1–10 employees. The company has raised a total of $2.38M across three funding rounds. In February 2022, PsyRx announced the appointment of Prof. Itamar Grotto as its new Executive Chairman of the Board, signaling a strengthening of its leadership team.
Business overview
PsyRx is a pharmaceutical R&D company focused on developing biological API psilocybin and ibogaine using bioreactor technology, adhering to GMP standards. The company aims to become a leading producer of GMP-standard ibogaine and psilocybin for pharmaceutical, food supplement, and other product development. Additionally, PsyRx is developing a novel antidepressant drug that combines ibogaine with existing approved antidepressants, seeking to enhance efficacy and reduce side effects by leveraging the synergistic effects of these compounds. The company operates within the Health Tech & Life Sciences sector, specifically targeting the Drugs Discovery & Development and Pharmaceuticals markets.
Strategic signal
In October 2023, PsyRx was featured in Haaretz for its innovative next-generation, plant-based solution for depression. This highlights the company's commitment to advancing mental health treatments through novel biological approaches, suggesting a strong focus on R&D and potential for market disruption in the pharmaceutical space.
Log in to access full profile ›Company Intelligence Q&A
- When was PsyRx founded?
- PsyRx was founded in October 2019.
- What is PsyRx's primary focus in drug development?
- PsyRx is focused on developing biological API psilocybin and ibogaine using bioreactor technology, adhering to GMP standards, and creating a revolutionary antidepressant drug combining ibogaine with existing antidepressants.
- What significant leadership change occurred at PsyRx?
- In February 2022, PsyRx announced the appointment of Prof. Itamar Grotto as its new Executive Chairman of the Board.
- What is the total capital raised by PsyRx?
- PsyRx has raised a total of $2.38M across three funding rounds.
- What was the focus of PsyRx's news coverage in October 2023?
- In October 2023, PsyRx was highlighted in Haaretz for its innovative next-generation, plant-based solution for depression.